Alaunos Therapeutics faces Nasdaq delisting and explores strategic alternatives to regain compliance.
SEC EDGAR, 2026-10-09: 8-K (Item 3.01) — "strategic alternatives"
Alaunos Therapeutics faces Nasdaq delisting and explores strategic alternatives to regain compliance.
Company: Alaunos Therapeutics, Inc. (TCRT) Filed: October 9, 2026, 8-K (Item 3.01) Phrase: "strategic alternatives" — "The Company is exploring and evaluating strategic alternatives intended to strengthen its financial position and support its efforts to regain compliance with Nasdaq’s applicable listing requirements." What the filing says: On October 5, 2026, the company received a written notice from Nasdaq informing it that its securities are subject to delisting because it failed to comply with Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2,500,000 in stockholders' equity. The company plans to request a hearing before the Nasdaq Hearings Panel to stay the delisting. It is working with a financial advisor to explore strategic alternatives and complete one or more potential transactions to strengthen its financial position and regain compliance. Two ways it goes: A. The company completes a transaction that satisfies Nasdaq's listing criteria and the Nasdaq Hearings Panel grants its request for continued listing. B. The company fails to complete a suitable transaction or the Nasdaq Hearings Panel denies its request, resulting in the delisting of its common stock. Next date: none named Watch: A decision by the Nasdaq Hearings Panel regarding the company's request for continued listing, or the announcement of a definitive agreement for a strategic transaction.